Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
CORALVILLE, Iowa, March 27, 2017 -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that Andrew Barrett, Ph.D., Senior Director, Scientific Affairs, will present at the Sachs Associates 2nd Annual Neuroscience Biopartnering and Investment Forum being held March 27, 2017, at the New York Academy of Sciences.
Details of KemPharm's presentation are as follows:
| Event: | 2nd Annual Neuroscience Biopartnering and Investment Forum | |
| Date: | Monday, March 27, 2017 | |
| Time: | 3:20 p.m. ET | |
| Location: | New York Academy of Sciences 7 World Trade Center 250 Greenwich St., 40th Floor (D Elevator Bank) New York, NY 10007 | |
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415, an extended-release prodrug of methylphenidate for the treatment of ADHD, and KP201/IR, an acetaminophen-free formulation of the company’s immediate release abuse deterrent hydrocodone product candidate, KP201. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected] Media Contact: Daniel L. Cohen Executive VP, Government and Public Relations KemPharm, Inc. 202-329-1825 [email protected]
